• Consensus Rating: Moderate Buy
  • Consensus Price Target: $134.64
  • Forecasted Upside: 17.88%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$114.22
▼ -1.1 (-0.95%)

This chart shows the closing price for DXCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DexCom Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXCM

Analyst Price Target is $134.64
▲ +17.88% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for DexCom in the last 3 months. The average price target is $134.64, with a high forecast of $151.00 and a low forecast of $100.00. The average price target represents a 17.88% upside from the last price of $114.22.

This chart shows the closing price for DXCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in DexCom. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/6/2022
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2022
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/5/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/3/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/1/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/30/2023
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/29/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$147.00 ➝ $151.00Low
1/3/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$131.00 ➝ $147.00Low
12/19/2023Piper SandlerBoost TargetOverweight ➝ Overweight$135.00 ➝ $150.00Low
12/13/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$110.00 ➝ $136.00Low
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$101.00 ➝ $122.00Low
10/27/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$98.00 ➝ $101.00Low
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$160.00 ➝ $100.00Low
10/16/2023Leerink PartnrsReiterated RatingOutperformLow
10/16/2023SVB LeerinkInitiated CoverageOutperform$110.00Low
10/10/2023Stifel NicolausLower TargetBuy ➝ Buy$155.00 ➝ $145.00Low
10/2/2023CitigroupLower Target$150.00 ➝ $115.00Low
9/29/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$131.00 ➝ $98.00Low
9/15/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$154.00 ➝ $131.00Low
9/6/2023UBS GroupLower TargetBuy ➝ Buy$175.00 ➝ $138.00Low
8/21/2023Robert W. BairdLower TargetOutperform ➝ Outperform$153.00 ➝ $130.00Low
7/31/2023BarclaysBoost TargetEqual Weight$115.00 ➝ $138.00Low
7/28/2023Canaccord Genuity GroupBoost TargetBuy$135.00 ➝ $150.00Low
7/28/2023Raymond JamesBoost Target$140.00 ➝ $154.00Low
7/28/2023Piper SandlerBoost TargetOverweight$150.00 ➝ $160.00Low
7/28/2023OppenheimerBoost Target$135.00 ➝ $150.00Low
7/28/2023Robert W. BairdBoost Target$145.00 ➝ $153.00Low
7/10/2023CitigroupBoost Target$146.00 ➝ $150.00Low
6/26/2023BTIG ResearchBoost Target$134.00 ➝ $150.00Low
5/30/2023Morgan StanleyInitiated CoverageEqual Weight$131.00Low
5/1/2023BarclaysBoost Target$110.00 ➝ $115.00Low
4/28/2023Stifel NicolausBoost Target$130.00 ➝ $140.00Low
4/28/2023UBS GroupBoost Target$142.00 ➝ $150.00Low
4/28/2023BTIG ResearchBoost Target$132.00 ➝ $134.00Low
4/28/2023Raymond JamesBoost Target$138.00 ➝ $140.00Low
4/17/2023BTIG ResearchBoost TargetBuy$126.00 ➝ $132.00Low
4/17/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$127.00 ➝ $138.00Low
3/28/2023UBS GroupInitiated CoverageBuy$142.00Low
2/13/2023BarclaysBoost TargetEqual Weight$103.00 ➝ $110.00Low
2/10/2023CowenBoost TargetOutperform$114.00 ➝ $125.00Low
1/26/2023Wolfe ResearchInitiated CoverageOutperform$121.00N/A
1/6/2023Morgan StanleyBoost TargetEqual Weight$117.00 ➝ $131.00Low
12/20/2022Stifel NicolausBoost Target$120.00 ➝ $130.00Low
12/12/2022CitigroupBoost TargetBuy$117.00 ➝ $146.00Low
11/1/2022Piper SandlerBoost Target$130.00Low
11/1/2022BTIG ResearchBoost Target$126.00Low
10/28/2022Raymond JamesBoost TargetOutperform$101.00 ➝ $125.00Low
10/28/2022Morgan StanleyBoost TargetEqual Weight$107.00 ➝ $117.00Low
10/28/2022Wells Fargo & CompanyBoost TargetOverweight$102.00 ➝ $128.00Low
10/28/2022CowenBoost Target$85.00 ➝ $114.00Low
10/28/2022CowenBoost Target$85.00 ➝ $114.00Low
10/28/2022CitigroupBoost Target$105.00 ➝ $117.00Low
10/28/2022Robert W. BairdBoost Target$97.00 ➝ $120.00Low
10/17/2022BarclaysInitiated CoverageEqual Weight$103.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$125.00Low
10/11/2022Morgan StanleyBoost TargetEqual Weight$83.00 ➝ $107.00Low
10/10/2022BTIG ResearchBoost TargetBuy$92.00 ➝ $110.00Low
10/7/2022Piper SandlerBoost TargetOverweight$110.00 ➝ $120.00Low
10/7/2022Stifel NicolausBoost TargetBuy$112.00 ➝ $120.00Low
7/29/2022CowenReiterated RatingBuy$85.00Low
7/29/2022OppenheimerLower Target$131.00 ➝ $105.00Low
7/29/2022Wells Fargo & CompanyLower Target$144.00 ➝ $102.00Low
7/29/2022Piper SandlerLower TargetOverweight$120.00 ➝ $110.00Low
7/29/2022Morgan StanleyLower TargetEqual Weight$91.00 ➝ $83.00Low
7/29/2022Robert W. BairdLower Target$115.00 ➝ $97.00Low
7/29/2022CitigroupLower Target$105.00 ➝ $100.00Low
7/15/2022Sanford C. BernsteinInitiated CoverageOutperform$105.00Low
6/24/2022BTIG ResearchLower TargetBuy$135.00 ➝ $105.00Low
6/13/2022Morgan StanleyLower TargetEqual Weight$90.75N/A
6/7/2022Morgan StanleyLower TargetEqual Weight$123.00 ➝ $90.75Medium
5/17/2022CitigroupLower TargetBuy$157.50 ➝ $131.25N/A
4/29/2022SVB LeerinkLower Target$141.25 ➝ $125.00High
4/29/2022Canaccord Genuity GroupLower Target$131.25 ➝ $125.00Medium
4/29/2022Raymond JamesLower Target$134.50 ➝ $121.50Medium
4/29/2022Piper SandlerLower Target$181.25 ➝ $120.00Medium
4/18/2022BTIG ResearchBoost Target$133.75 ➝ $140.00High
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyMedium
2/11/2022Robert W. BairdLower Target$156.25 ➝ $140.00Medium
2/11/2022Morgan StanleyLower TargetEqual Weight$142.50 ➝ $128.50Medium
2/11/2022CitigroupLower Target$165.00 ➝ $157.50Medium
2/3/2022BTIG ResearchUpgradeNeutral ➝ Buy$133.75High
1/19/2022Raymond JamesLower TargetOutperform$154.50 ➝ $134.50Low
1/19/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$143.75Low
1/7/2022Morgan StanleyLower TargetEqual Weight$144.00 ➝ $142.50High
1/7/2022GuggenheimUpgradeNeutral ➝ Buy$145.00High
11/1/2021Raymond JamesBoost TargetOutperform$128.75 ➝ $154.50Low
10/29/2021Jefferies Financial GroupBoost TargetBuy$152.50 ➝ $163.75High
10/29/2021OppenheimerBoost TargetOutperform$131.25 ➝ $156.25High
10/29/2021SVB LeerinkBoost TargetOutperform$125.00 ➝ $178.75High
10/29/2021Morgan StanleyBoost TargetEqual Weight$127.50 ➝ $144.00High
10/29/2021CitigroupBoost TargetBuy$157.50 ➝ $165.00High
10/29/2021Robert W. BairdBoost TargetOutperform$130.00 ➝ $156.25High
10/29/2021Piper SandlerBoost TargetOverweight$162.50 ➝ $168.75High
10/18/2021GuggenheimDowngradeBuy ➝ NeutralMedium
10/1/2021CitigroupBoost TargetBuy$132.50 ➝ $157.50Medium
9/16/2021Piper SandlerBoost TargetOverweight$137.50 ➝ $162.50High
8/2/2021Morgan StanleyBoost TargetEqual Weight$102.50 ➝ $127.50Low
7/30/2021StephensBoost TargetOverweight$117.00 ➝ $136.50High
7/30/2021Wells Fargo & CompanyBoost TargetEqual Weight$95.00 ➝ $118.75High
7/30/2021SVB LeerinkBoost TargetOutperform$121.25 ➝ $125.00High
7/30/2021OppenheimerBoost TargetOutperform$125.00 ➝ $131.25High
7/30/2021Raymond JamesBoost TargetOutperform$116.50 ➝ $128.75High
7/30/2021Robert W. BairdBoost TargetOutperform$115.00 ➝ $130.00High
7/30/2021Piper SandlerBoost TargetOverweight$125.00 ➝ $137.50High
7/21/2021CowenLower TargetOutperform$135.00 ➝ $131.25Low
7/1/2021StephensReiterated RatingBuy$117.00Low
5/28/2021Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$95.00High
5/24/2021BarclaysInitiated CoverageOverweight$125.00Medium
4/30/2021CitigroupBoost Target$120.00 ➝ $122.00High
4/30/2021Raymond JamesBoost TargetOutperform$112.25 ➝ $116.50High
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$109.50Medium
2/12/2021CitigroupLower TargetBuy$121.25 ➝ $120.00Low
2/12/2021OppenheimerBoost TargetOutperform$103.75 ➝ $112.25Low
2/12/2021Morgan StanleyBoost TargetEqual Weight$100.50 ➝ $102.50Low
2/12/2021Raymond JamesBoost TargetOutperform$103.75 ➝ $112.25Low
1/29/2021Piper SandlerBoost TargetOverweight$116.25 ➝ $125.00High
1/6/2021UBS GroupUpgradeNeutral ➝ Buy$102.50 ➝ $111.25N/A
12/15/2020Morgan StanleyBoost TargetEqual Weight$99.50 ➝ $100.50Low
12/10/2020Raymond JamesReiterated RatingBuyHigh
11/20/2020Piper SandlerReiterated RatingBuy$116.25Medium
10/28/2020Stifel NicolausLower TargetBuy$125.00 ➝ $118.75High
10/28/2020Raymond JamesLower TargetOutperform$112.50 ➝ $109.50High
10/28/2020Morgan StanleyLower TargetEqual Weight$107.00 ➝ $99.50High
10/2/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$105.00 ➝ $87.50High
7/29/2020UBS GroupBoost TargetNeutral$83.75 ➝ $100.00High
7/29/2020Morgan StanleyBoost TargetEqual Weight$94.25 ➝ $107.00Low
7/29/2020Raymond JamesBoost TargetOutperform$98.75 ➝ $112.50Low
7/29/2020Stifel NicolausBoost TargetBuy$96.25 ➝ $125.00Low
7/29/2020SVB LeerinkBoost TargetEqual Weight ➝ Outperform$116.25 ➝ $121.25Medium
7/29/2020CitigroupBoost TargetBuy$110.00 ➝ $121.25Medium
7/29/2020Piper SandlerBoost TargetOverweight$112.50 ➝ $116.25Medium
7/28/2020OppenheimerInitiated CoverageBuy$90.00 ➝ $111.25High
7/28/2020Bank of AmericaReiterated RatingBuy$125.00High
7/27/2020JPMorgan Chase & Co.Boost TargetOverweight$90.00 ➝ $112.50Medium
7/7/2020CowenBoost TargetPositive ➝ Outperform$107.50 ➝ $112.50Low
6/17/2020Bank of AmericaBoost TargetBuy$93.75 ➝ $125.00Low
6/9/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $98.75High
6/3/2020CitigroupBoost TargetAverage ➝ Buy$90.25 ➝ $110.00Medium
5/27/2020Piper SandlerBoost TargetOverweight$93.75 ➝ $112.50High
5/14/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$105.00Low
4/30/2020UBS GroupBoost TargetNeutral$68.75 ➝ $83.75Medium
4/29/2020GuggenheimBoost TargetBuy$96.25 ➝ $98.75High
4/29/2020CitigroupBoost TargetBuy$82.50 ➝ $90.25High
4/29/2020Morgan StanleyBoost TargetEqual Weight$69.50 ➝ $94.25Medium
4/29/2020JPMorgan Chase & Co.Boost TargetOverweight$75.00 ➝ $90.00Medium
4/29/2020Stifel NicolausBoost TargetBuy$67.50 ➝ $96.25Medium
4/29/2020OppenheimerBoost TargetOutperform$76.25 ➝ $90.00High
4/29/2020CowenBoost TargetOutperform$75.00 ➝ $90.00High
4/29/2020Robert W. BairdBoost TargetOutperform$74.00 ➝ $93.25High
4/29/2020Piper SandlerBoost TargetOverweight$75.00 ➝ $93.75High
4/29/2020BTIG ResearchReiterated RatingHoldHigh
4/27/2020Raymond JamesBoost TargetOutperform$72.00 ➝ $87.50Low
4/24/2020SVB LeerinkBoost TargetOutperform$79.00 ➝ $96.25Medium
3/27/2020Morgan StanleyBoost TargetEqual Weight$67.50 ➝ $69.50High
3/23/2020StephensLower TargetOverweight$75.00 ➝ $60.00Low
3/6/2020OppenheimerBoost TargetOutperform$71.25 ➝ $76.25Low
3/4/2020CitigroupInitiated CoverageBuy$82.50 ➝ $82.50Low
2/18/2020Morgan StanleyBoost TargetEqual Weight$56.25 ➝ $67.50High
2/14/2020Piper SandlerBoost Target$57.50 ➝ $75.00Low
2/14/2020CfraBoost TargetHold$51.25 ➝ $64.50High
2/14/2020OppenheimerBoost TargetOutperform$62.50 ➝ $71.25High
2/14/2020CowenReiterated RatingOutperform$62.50 ➝ $75.00High
2/14/2020GuggenheimReiterated RatingBuy$61.25 ➝ $75.00High
2/14/2020StephensBoost TargetOverweight$63.75 ➝ $75.00High
2/14/2020UBS GroupBoost TargetNeutral$62.50 ➝ $68.75High
2/14/2020Raymond JamesBoost TargetOutperform$64.50 ➝ $72.00High
2/14/2020Stifel NicolausBoost TargetBuy$62.50 ➝ $75.00High
1/7/2020CowenReiterated RatingBuy$62.50High
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$53.75 ➝ $63.75Low
12/18/2019Bank of AmericaReiterated RatingBuy$55.00 ➝ $62.50Low
12/17/2019Morgan StanleyBoost TargetEqual Weight$50.50 ➝ $56.25Medium
12/16/2019Piper Sandler CompaniesReiterated RatingBuy$57.50Medium
11/18/2019Piper Sandler CompaniesReiterated RatingOverweightHigh
11/7/2019OppenheimerBoost Target$45.00 ➝ $51.25Medium
11/7/2019Raymond JamesBoost TargetOutperform$43.00 ➝ $47.25High
11/7/2019Robert W. BairdBoost TargetOutperform$48.75 ➝ $60.00High
11/7/2019Jefferies Financial GroupBoost TargetBuy$45.00 ➝ $50.00High
11/7/2019JPMorgan Chase & Co.Reiterated RatingOverweight$47.50 ➝ $53.75High
11/7/2019GuggenheimUpgradeNeutral ➝ BuyHigh
10/22/2019Stifel NicolausInitiated CoverageBuy$47.50High
9/23/2019Piper Sandler CompaniesSet TargetBuy$45.50Medium
9/3/2019BMO Capital MarketsBoost TargetOutperform$45.00 ➝ $47.50Low
8/29/2019Robert W. BairdBoost TargetOutperform$46.50 ➝ $48.75Low
8/1/2019OppenheimerBoost Target$41.75 ➝ $45.00Medium
8/1/2019Bank of AmericaBoost TargetBuy$40.50 ➝ $46.25Medium
8/1/2019Robert W. BairdBoost TargetOutperform$45.00 ➝ $46.50High
8/1/2019JPMorgan Chase & Co.Boost TargetOverweight$42.50 ➝ $47.50High
8/1/2019UBS GroupBoost TargetNeutral$35.00 ➝ $40.00High
8/1/2019Raymond JamesBoost TargetOutperform$37.50 ➝ $43.00High
8/1/2019BTIG ResearchReiterated RatingHoldHigh
7/31/2019Piper Sandler CompaniesBoost TargetOverweight ➝ Positive$43.25 ➝ $45.50High
7/15/2019Piper Sandler CompaniesSet TargetBuy$43.25High
6/6/2019Northland SecuritiesReiterated RatingHold$31.25High
5/2/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$41.75 ➝ $43.00High
5/2/2019Raymond JamesLower TargetOutperform ➝ Outperform$40.00 ➝ $37.50High
5/1/2019Piper Sandler CompaniesBoost TargetOverweight$43.25High
4/30/2019UBS GroupLower TargetNeutral ➝ Neutral$37.50 ➝ $35.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 30 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2023
  • 18 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2023
  • 20 very positive mentions
  • 23 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
10/1/2023
  • 25 very positive mentions
  • 28 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
10/31/2023
  • 20 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 35 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 33 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/29/2024
  • 47 very positive mentions
  • 37 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 47 very positive mentions
  • 37 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $114.22
Low: $113.05
High: $115.68

50 Day Range

MA: $122.54
Low: $114.22
High: $129.70

52 Week Range

Now: $114.22
Low: $74.75
High: $139.55

Volume

2,763,970 shs

Average Volume

2,963,136 shs

Market Capitalization

$44.03 billion

P/E Ratio

87.19

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of DexCom?

The following equities research analysts have issued research reports on DexCom in the last year: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., JPMorgan Chase & Co., Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for DXCM.

What is the current price target for DexCom?

14 Wall Street analysts have set twelve-month price targets for DexCom in the last year. Their average twelve-month price target is $134.64, suggesting a possible upside of 17.9%. Raymond James has the highest price target set, predicting DXCM will reach $151.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $100.00 for DexCom in the next year.
View the latest price targets for DXCM.

What is the current consensus analyst rating for DexCom?

DexCom currently has 2 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DXCM.

What other companies compete with DexCom?

How do I contact DexCom's investor relations team?

DexCom's physical mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 200-0200 and its investor relations email address is [email protected]. The official website for DexCom is www.dexcom.com. Learn More about contacing DexCom investor relations.